Candel Therapeutics, Inc. (CADL) Misses Q4 EPS by 29c
Tweet
Share
E-mailGet Alerts CADL Hot Sheet
Join SI Premium – FREE
Candel Therapeutics, Inc. (NASDAQ: CADL) reported Q4 EPS of ($0.54), $0.29 worse than the analyst estimate of ($0.25).
For earnings history and earnings-related data on Candel Therapeutics, Inc. (CADL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
- AXIL Brands (AXIL) Tops Q4 EPS by 4c
- La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
